Chronic Kidney Disease Associated With Increased Risk of Renal and Urothelial Cancers
Does renal disease increase one's risk of developing cancer?
Shifting the Paradigm?: Where Is Chemotherapy-and Particularly, High-Dose Therapy-Going in the Era of Biologic Agents?
The changes seen in multiple myeloma are a perfect illustration of a potentially shifting paradigm in cancer care.
Advancing Prostate Cancer Care
The prostate cancer team at the Comprehensive Cancer Center at Wake Forest Baptist Medical Center has recently focused on two primary areas: minimally invasive care and clinical research.
Tumor Infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer
A high level of tumor infiltrating lymphocytes (TILs) may be a marker of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer, especially in patients with triple-negative or HER2-positive disease
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512